Could a common diabetes pill treat anemia in MDS patients?
NCT ID NCT07516847
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can help treat anemia in people with lower-risk myelodysplastic syndromes (MDS). Anemia is a common problem in MDS, causing fatigue and often requiring blood transfusions. The trial will give 37 participants dapagliflozin daily for 24 weeks to see if it raises hemoglobin levels and reduces transfusion needs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dapagliflozin (a diabetes drug, also known as Forxiga)
- What this could lead to
- If it works, this could offer a new treatment option for anemia in lower-risk MDS patients, potentially reducing fatigue and the need for blood transfusions.
- What could go wrong
- This is a small, early-phase trial with only 37 participants and no placebo group. The drug may not improve anemia significantly, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can less be more? testing transfusion limits in ECMO
- A simple blood test trend may flag ICU patients at risk
- Rethinking anemia: does blood hemoglobin tell the whole story?
- A simple nutrient may shield Babies' brains from iron deficiency
- School health rooms and trained teachers: a new hope for Zambia's children?
- Can a pill replace EPO shots for anemia in kidney disease?